Daptomycin versus Glycopeptides for the Treatment of
Enterococcus faecium
bacteraemia
bloodstream infection
daptomycin
glycopeptides
vancomycin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
14 Jun 2021
14 Jun 2021
Historique:
received:
12
05
2021
revised:
11
06
2021
accepted:
13
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Ampicillin resistant and glycopeptide susceptible This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay. From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar. Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.
Sections du résumé
BACKGROUND
BACKGROUND
Ampicillin resistant and glycopeptide susceptible
METHODS
METHODS
This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay.
RESULTS
RESULTS
From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar.
CONCLUSIONS
CONCLUSIONS
Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.
Identifiants
pubmed: 34198646
pii: antibiotics10060716
doi: 10.3390/antibiotics10060716
pmc: PMC8232223
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29760141
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Ann Pharmacother. 2021 Jul;55(7):846-855
pubmed: 33147997
Clin Infect Dis. 2020 Mar 3;70(6):1240-1246
pubmed: 31504338
Clin Infect Dis. 2007 Sep 15;45 Suppl 3:S191-5
pubmed: 17712746
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78
pubmed: 22421879
Clin Microbiol Infect. 2016 Oct;22(10):890.e1-890.e7
pubmed: 27475738
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Antimicrob Agents Chemother. 2014;58(2):734-9
pubmed: 24247127
Clin Microbiol Infect. 2020 Aug;26(8):1039-1043
pubmed: 32353412
BMC Med. 2014 Mar 06;12:40
pubmed: 24597462
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32094136
Intensive Care Med. 2020 Feb;46(2):353-356
pubmed: 31792686
J Antimicrob Chemother. 2008 Dec;62(6):1203-6
pubmed: 18765412
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Clin Infect Dis. 2001 Feb 15;32(4):587-94
pubmed: 11181122
Clin Infect Dis. 2013 Jul;57(2):208-16
pubmed: 23580739
J Antimicrob Chemother. 2018 Jan 1;73(1):1-11
pubmed: 29059358
Clin Microbiol Infect. 2013 Sep;19(9):860-8
pubmed: 23039210
Clin Infect Dis. 2017 Apr 15;64(8):1026-1034
pubmed: 28329222
Int J Antimicrob Agents. 2019 Nov;54(5):572-578
pubmed: 31476435
Expert Opin Pharmacother. 2018 Jun;19(9):979-992
pubmed: 29877755
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31235559
Enferm Infecc Microbiol Clin. 2010 Jun-Jul;28(6):342-8
pubmed: 19783077
Clin Infect Dis. 2019 May 2;68(10):1650-1657
pubmed: 30188976
Antibiotics (Basel). 2019 Nov 29;8(4):
pubmed: 31795437
Clin Microbiol Rev. 2019 Jan 30;32(2):
pubmed: 30700430
Int J Clin Pract. 2016 Feb;70(2):147-55
pubmed: 26817569
Clin Infect Dis. 2015 Sep 15;61(6):871-8
pubmed: 26063715
Clin Infect Dis. 2010 Jun 15;50(12):1568-74
pubmed: 20462352
Ann Pharmacother. 2015 Jan;49(1):69-85
pubmed: 25352037
Clin Infect Dis. 2016 Jun 15;62(12):1514-1520
pubmed: 27045126
J Clin Microbiol. 2019 Jun 25;57(7):
pubmed: 31092593
Open Forum Infect Dis. 2015 Oct 29;2(4):ofv156
pubmed: 26677455
Epidemiol Infect. 2018 Dec;146(16):2028-2035
pubmed: 30165917
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Clin J Am Soc Nephrol. 2006 Nov;1(6):1314-9
pubmed: 17699363
Expert Opin Pharmacother. 2019 Dec;20(18):2317-2334
pubmed: 31622115
J Infect Dis. 2020 Oct 1;222(9):1531-1539
pubmed: 32514561
Ann Intern Med. 2004 Jan 6;140(1):26-32
pubmed: 14706969